{
  "1PG.MU": {
    "city": "Lysaker",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Aker BioMarine AS",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "AKER BIOMARINE ASA  NK 6",
    "state": null,
    "summary": "Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa. It operates in two segments, Ingredients and Brands. The company provides krill oil products, including omega-3s, phospholipids, choline, and astaxanthin under the Superba, Kori, NKO, and KÂ·REAL brands. It also offers Qrill aqua nutrient-rich feed ingredients for aquaculture; and QRILL pet, a functional ingredient for pet food. The company also offers LYSOVETA, a delivery platform based on LPC-bound EPA and DHA from krill; and INVI, a hydrolyzed protein isolate for food and beverage applications. In addition, it distributes human health and nutrition products, and natural supplements, as well as provides AION, a circular solution provider that recycles waste into products, such as shopping baskets and food trays. Aker BioMarine AS has an agreement with Medical Food Solutions Research to develop pharmaceutical therapies for brain and eye health based on Lysoveta. The company is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.",
    "website": "http://www.akerbiomarine.com",
    "zipcode": "1327"
  },
  "3Z6.F": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "NattoPharma ASA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NATTOPHARMA ASA  NK 3",
    "state": null,
    "summary": "As of March 23, 2021, NattoPharma ASA operates as a subsidiary of Compagnie Des Levures Lesaffre SA.",
    "website": "http://www.nattopharma.com",
    "zipcode": "0283"
  },
  "7BG.F": {
    "city": "Bergen",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "BerGenBio ASA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BERGENBIO ASA",
    "state": null,
    "summary": "BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. The company's Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase I clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is headquartered in Bergen, Norway.",
    "website": "http://www.bergenbio.com",
    "zipcode": "5009"
  },
  "7UM.F": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Ultimovacs ASA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ULTIMOVACS AS  DK1",
    "state": null,
    "summary": "Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company engages in performing a clinical development program with clinical trials in Europe and the United States. Its lead product candidate is UV1, a peptide-based vaccine, which completed Phase I clinical trial that induces T cell response against the universal cancer antigen telomerase. The company was founded in 2011 and is headquartered in Oslo, Norway.",
    "website": "http://www.ultimovacs.com",
    "zipcode": "0379"
  },
  "8NN.F": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Nordic Nanovector ASA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NORDIC NANOVECTOR NK 0,20",
    "state": null,
    "summary": "Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway and internationally. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. Nordic Nanovector ASA has collaboration agreements with Paul Scherrer Institute; Areva Med; LegoChem Bio; and Heidelberg Pharma. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.",
    "website": "http://www.nordicnanovector.com",
    "zipcode": "0884"
  },
  "8U5.MU": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Biotechnology",
    "long_name": "Circa Group AS",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CIRCA GROUP  NK 1",
    "state": null,
    "summary": "Circa Group AS engages in production and sale of biochemicals from waste biomass. Its products include Levoglucosenone, a valuable platform molecule; Cyrene, a chiral dipolar aprotic solvent from renewable cellulose; and Laiscent, a nature identical molecule. The company was founded in 2006 and is based in Oslo, Norway.",
    "website": "http://circa-group.com",
    "zipcode": "0278"
  },
  "ABS.OL": {
    "city": "Ãrsta",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Biotechnology",
    "long_name": "Arctic Bioscience AS",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ARCTIC BIOSCIENCE",
    "state": null,
    "summary": "Arctic Bioscience AS, a biotechnology company, provides nutraceutical and pharmaceutical products. It designs, produces, and sells intermediary and finished food supplements to businesses and consumers. The company is also developing a pharmaceutical product candidate HRO350, a novel oral treatment for mild-to-moderate psoriasis. In addition, it provides a subscription service for its nutraceutical Romega branded capsules. It serves in China, Hong Kong, Macao, Chile, France, Spain, Portugal, Germany, Poland, Austria, and internationally. Arctic Bioscience AS was incorporated in 2011 and is based in Ãrsta, Norway.",
    "website": "http://www.arctic-bioscience.com",
    "zipcode": "6155"
  },
  "ABT.OL": {
    "city": "Lysaker",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Biotechnology",
    "long_name": "Aqua Bio Technology ASA",
    "market": "no_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AQUA BIO TECHNOLOG",
    "state": null,
    "summary": "Aqua Bio Technology ASA engages in developing and commercializing active ingredients for use in skin care products in Norway. It offers Aquabeautine XL, a proprietary ingredient; and Spirulysat, an antioxidant for cosmetic use. The company also markets and distributes natural and skin care products to consumers, retailers, and professionals in Europe and the Middle East. It distributes its products through Internet, stores, and skin care clinics. The company markets and distributes organic skin care products under the Moana brand name in New Zealand and arctic skin care products under the Cuvget brand name in Norway. Aqua Bio Technology ASA was founded in 2000 and is based in Lysaker, Norway.",
    "website": "http://www.aquabiotechnology.com",
    "zipcode": "1366"
  },
  "AKBM.OL": {
    "city": "Lysaker",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Aker BioMarine AS",
    "market": "no_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "AKER BIOMARINE ASA",
    "state": null,
    "summary": "Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa. It operates in two segments, Ingredients and Brands. The company provides krill oil products, including omega-3s, phospholipids, choline, and astaxanthin under the Superba, Kori, NKO, and KÂ·REAL brands. It also offers Qrill aqua nutrient-rich feed ingredients for aquaculture; and QRILL pet, a functional ingredient for pet food. The company also offers LYSOVETA, a delivery platform based on LPC-bound EPA and DHA from krill; and INVI, a hydrolyzed protein isolate for food and beverage applications. In addition, it distributes human health and nutrition products, and natural supplements, as well as provides AION, a circular solution provider that recycles waste into products, such as shopping baskets and food trays. Aker BioMarine AS has an agreement with Medical Food Solutions Research to develop pharmaceutical therapies for brain and eye health based on Lysoveta. The company is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.",
    "website": "http://www.akerbiomarine.com",
    "zipcode": "1327"
  },
  "AZT.OL": {
    "city": "TromsÃ¸",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Biotechnology",
    "long_name": "ArcticZymes Technologies ASA",
    "market": "no_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ARCTICZYMES TECH",
    "state": null,
    "summary": "ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and markets recombinant enzymes derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics (IVD), and therapeutics in Norway, Europe, Asia, Australia, Africa, and the Americas. It offers shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing (NGS) processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; salt active nuclease for the removal of nucleic acids during manufacturing of vaccines, viruses, recombinant proteins, and other reagents; and ligases for joining DNA fragments. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in TromsÃ¸, Norway.",
    "website": "http://arcticzymes.com",
    "zipcode": "9294"
  },
  "B4V.F": {
    "city": "TromsÃ¸",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "ArcticZymes Technologies ASA",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ARCTICZYMES TECH ASA NK 1",
    "state": null,
    "summary": "ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and markets recombinant enzymes derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics (IVD), and therapeutics in Norway, Europe, Asia, Australia, Africa, and the Americas. It offers shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing (NGS) processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; salt active nuclease for the removal of nucleic acids during manufacturing of vaccines, viruses, recombinant proteins, and other reagents; and ligases for joining DNA fragments. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in TromsÃ¸, Norway.",
    "website": "http://arcticzymes.com",
    "zipcode": "9294"
  },
  "BGBIO.OL": {
    "city": "Bergen",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Biotechnology",
    "long_name": "BerGenBio ASA",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BERGENBIO ASA",
    "state": null,
    "summary": "BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. The company's Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase I clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is headquartered in Bergen, Norway.",
    "website": "http://www.bergenbio.com",
    "zipcode": "5009"
  },
  "BRRGF": {
    "city": "Bergen",
    "country": "Norway",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "BerGenBio ASA",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BERGENBIO ASA",
    "state": null,
    "summary": "BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. The company's Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase I clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is headquartered in Bergen, Norway.",
    "website": "http://www.bergenbio.com",
    "zipcode": "5009"
  },
  "C34.F": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "Carasent ASA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CARASENT ASA  NK 1,332",
    "state": null,
    "summary": "Carasent ASA, an investment management company, provides cloud-based medical record services to the private and public health care industry in the Nordic region. The company develops Webdoc, a cloud based EMR-system; and digital platform for interactive health care that enables healthcare providers to communicate with their patients through digital services, such as video, chat, and other channels. It also provides Ad Voca, a Web application; Ad Opus; and smart integration solutions. The company was formerly known as Apptix ASA and changed its name to Carasent ASA in May 2019. Carasent ASA was founded in 1997 and is based in Oslo, Norway.",
    "website": "http://carasent.com",
    "zipcode": "0164"
  },
  "CARA.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Health Information Services",
    "long_name": "Carasent ASA",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CARASENT ASA",
    "state": null,
    "summary": "Carasent ASA, an investment management company, provides cloud-based medical record services to the private and public health care industry in the Nordic region. The company develops Webdoc, a cloud based EMR-system; and digital platform for interactive health care that enables healthcare providers to communicate with their patients through digital services, such as video, chat, and other channels. It also provides Ad Voca, a Web application; Ad Opus; and smart integration solutions. The company was formerly known as Apptix ASA and changed its name to Carasent ASA in May 2019. Carasent ASA was founded in 1997 and is based in Oslo, Norway.",
    "website": "http://carasent.com",
    "zipcode": "0164"
  },
  "CIRCA.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Biotechnology",
    "long_name": "Circa Group AS",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CIRCA GROUP AS",
    "state": null,
    "summary": "Circa Group AS engages in production and sale of biochemicals from waste biomass. Its products include Levoglucosenone, a valuable platform molecule; Cyrene, a chiral dipolar aprotic solvent from renewable cellulose; and Laiscent, a nature identical molecule. The company was founded in 2006 and is based in Oslo, Norway.",
    "website": "http://circa-group.com",
    "zipcode": "0278"
  },
  "CSAM.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Health Information Services",
    "long_name": "CSAM Health Group AS",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CSAM HEALTH GROUP",
    "state": null,
    "summary": "CSAM Health Group AS provides various ehealth solutions in Norway, Sweden, Denmark, Finland, Spain, the United Kingdom, and the Philippines. The company offers CSAM Arcidis, an integrated system for teleradiology; CSAM Cardio, an ECG and diagnostic storage tool; CSAM DICOM Server for handling radiology data; CSAM HelseMail for transfer of confidential patient data between healthcare organizations; CSAM Infobroker, a vendor-neutral telemedicine system for radiology that enables multiple clinicians to share resources and knowledge; CSAM S7, a platform for self-care and health counselling; CSAM Web Client, a web-based user interface and connectivity solution that allows users to access multiple CSAM applications and functions; and CSAM XDS, a central archive for storing and managing various types of clinical patient data. It also provides CSAM CIMA, a mobile application for capturing, using, and sending medical media via mobile technology; CSAM Picsara, an image management solution that enables image capture, storing, and archiving in real time; CSAM Media, a web-based medical imaging solution; CSAM Medimaker for image management and workflow solution; and CSAM TRIS, a radiology information system. In addition, the company offers CSAM Partus, a maternity information system; CSAM Natus, a maternity care system; CSAM iPana Labor Information System, a web-based labour information system; CSAM iPana Maternity, a cloud-based service platform that enables expectant mothers, hospitals, and maternity clinics to electronically collect, store, and share important medical information; and CSAM LinnÃ©Filer, a care and practice management software for ART clinics. Further, it provides CSAM AMIS, an emergency medical information system; CSAM Interactive Manchester Triage System (IMTS), an electronic tool for assessing and prioritizing patients based on the gold-standard Manchester triage scale; CSAM Paratus, an emergency response system in Sweden; CSAM Cytodose, an oncology management solution in the Nordics; and CSAM ProSang, an advanced laboratory information management system. The company was founded in 1999 and is headquartered in Oslo, Norway.",
    "website": "http://www.csamhealth.com",
    "zipcode": "0283"
  },
  "EXTX.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Biotechnology",
    "long_name": "EXACT Therapeutics AS",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "EXACT THERAPEUTICS",
    "state": null,
    "summary": "EXACT Therapeutics AS, a clinical stage biotech company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology, infectious diseases, and neurological conditions. EXACT Therapeutics AS has a collaboration with GE Healthcare to develop an ultrasound probe to be used in studies using acoustic cluster therapy across various disease conditions. The company was founded in 2012 and is based in Oslo, Norway.",
    "website": "http://www.exact-tx.com",
    "zipcode": "0581"
  },
  "GENT.OL": {
    "city": "Moss",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Diagnostics & Research",
    "long_name": "Gentian Diagnostics AS",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GENTIAN DIAGNO ASA",
    "state": null,
    "summary": "Gentian Diagnostics AS researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, the United States. It offers in-vitro diagnostic (IVD) for medical laboratories and universities. The company's products include the gentian calprotectin immunoassay used for the measurement of calprotectin in plasma and serum in the diagnosis of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; and Canine CRP, an IVD test for the quantitative determination of Canine CRP in dog serum plasma. It also develops NT-proBNP Immunoassay, a turbidimetric in vitro diagnostic test for the quantitative measurement of N-terminal pro-brain natriuretic peptide. The company was founded in 2001 and is headquartered in Moss, Norway.",
    "website": "http://www.gentian.com",
    "zipcode": "1596"
  },
  "HBC.OL": {
    "city": "Ãlesund",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Biotechnology",
    "long_name": "Hofseth BioCare ASA",
    "market": "no_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "HOFSETH BIOCARE AS",
    "state": null,
    "summary": "Hofseth BioCare ASA provides value added biomarine ingredients for human, pets, and animal feed markets in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals; and CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ãlesund, Norway.",
    "website": "http://www.hofsethbiocare.no",
    "zipcode": "6005"
  },
  "HBQ.F": {
    "city": "Ãlesund",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Hofseth BioCare ASA",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "HOFSETH BIOCARE  NK 0,01",
    "state": null,
    "summary": "Hofseth BioCare ASA provides value added biomarine ingredients for human, pets, and animal feed markets in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals; and CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ãlesund, Norway.",
    "website": "http://www.hofsethbiocare.no",
    "zipcode": "6005"
  },
  "HOFBF": {
    "city": "Ãlesund",
    "country": "Norway",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Hofseth BioCare ASA",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "HOFSETH BIOCARE AS",
    "state": null,
    "summary": "Hofseth BioCare ASA provides value added biomarine ingredients for human, pets, and animal feed markets in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals; and CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ãlesund, Norway.",
    "website": "http://www.hofsethbiocare.no",
    "zipcode": "6005"
  },
  "INDCT.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Health Information Services",
    "long_name": "Induct Software AS",
    "market": "no_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "INDUCT AS",
    "state": null,
    "summary": "Induct Software AS offers cloud-based innovation communities delivered as software as a service. Its platform that enables organizations to create, manage, track, and measure the innovation process from idea creation through to final implementation and impact reporting. The company serves private enterprises, governments, education and science networks, and healthcare industries. Induct Software AS has a strategic partnership with ICREA to expand its market penetration and presence in the United States, Europe, Africa, Indian Subcontinent, and GCC and CIS countries. The company was founded in 2007 and is headquartered in Oslo, Norway.",
    "website": "http://www.inductsoftware.com",
    "zipcode": "0158"
  },
  "LIFE.OL": {
    "city": "Bergen",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Medical Devices",
    "long_name": "Lifecare AS",
    "market": "no_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIFECARE AS",
    "state": null,
    "summary": "Lifecare AS engages in the research and development of medical sensors for health monitoring in Norway. It develops Sencell, a long term implantable micro sensor for monitoring glucose levels. The company was founded in 2006 and is headquartered in Bergen, Norway.",
    "website": "http://www.lifecare.no",
    "zipcode": "5861"
  },
  "MD1.F": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Medistim ASA",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MEDISTIM ASA  NK -,25",
    "state": null,
    "summary": "Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.",
    "website": "http://www.medistim.com",
    "zipcode": "0579"
  },
  "MEDI.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Medical Devices",
    "long_name": "Medistim ASA",
    "market": "no_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MEDISTIM ASA",
    "state": null,
    "summary": "Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.",
    "website": "http://www.medistim.com",
    "zipcode": "0579"
  },
  "N1A.F": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Navamedic ASA",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NAVAMEDIC ASA  NK 1",
    "state": null,
    "summary": "Navamedic ASA, a pharmaceutical company, markets and sells pharmaceuticals and other health care products in Northern European region. The company's product portfolio includes generic, branded, and patented pharmaceuticals, as well as medical devices, food supplements, cosmetics, and other health care products. It also distributes medical nutrition products for various metabolic disorders, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia type 1, MMA/PA, IVA, renal, MCT, low protein, single dose amino acids, glycogen storage disease, and ketogenic diet, as well as other products. In addition, the company sells consumer care products consisting of non-prescription drugs and health care products primarily through pharmacies and drugstores. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Oslo, Norway.",
    "website": "http://www.navamedic.com",
    "zipcode": "0255"
  },
  "NANOV.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Biotechnology",
    "long_name": "Nordic Nanovector ASA",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NORDIC NANOVECTOR",
    "state": null,
    "summary": "Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway and internationally. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. Nordic Nanovector ASA has collaboration agreements with Paul Scherrer Institute; Areva Med; LegoChem Bio; and Heidelberg Pharma. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.",
    "website": "http://www.nordicnanovector.com",
    "zipcode": "0884"
  },
  "NATTO.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "NattoPharma ASA",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NATTOPHARMA ASA",
    "state": null,
    "summary": "As of March 23, 2021, NattoPharma ASA operates as a subsidiary of Compagnie Des Levures Lesaffre SA.",
    "website": "http://www.nattopharma.com",
    "zipcode": "0283"
  },
  "NAVA.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Navamedic ASA",
    "market": "no_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NAVAMEDIC ASA",
    "state": null,
    "summary": "Navamedic ASA, a pharmaceutical company, markets and sells pharmaceuticals and other health care products in Northern European region. The company's product portfolio includes generic, branded, and patented pharmaceuticals, as well as medical devices, food supplements, cosmetics, and other health care products. It also distributes medical nutrition products for various metabolic disorders, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia type 1, MMA/PA, IVA, renal, MCT, low protein, single dose amino acids, glycogen storage disease, and ketogenic diet, as well as other products. In addition, the company sells consumer care products consisting of non-prescription drugs and health care products primarily through pharmacies and drugstores. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Oslo, Norway.",
    "website": "http://www.navamedic.com",
    "zipcode": "0255"
  },
  "OBSRV.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Medical Devices",
    "long_name": "Observe Medical ASA",
    "market": "no_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "OBSERVE MEDICAL",
    "state": null,
    "summary": "Observe Medical ASA develops and markets medical technology products for patients, healthcare professionals, and hospitals in Europe and the United States. The company offers Sippi, a digital urine measuring system that automatically delivers data to electronic patient journal systems. It also develops Sippcoat, a technology that hampers the formation of biofilms in urine collection and drainage systems. The company was founded in 2009 and is headquartered in Oslo, Norway.",
    "website": "http://observemedical.com",
    "zipcode": "0255"
  },
  "OM5A.F": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Observe Medical ASA",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "OBSERVE MEDICAL ASA -,26",
    "state": null,
    "summary": "Observe Medical ASA develops and markets medical technology products for patients, healthcare professionals, and hospitals in Europe and the United States. The company offers Sippi, a digital urine measuring system that automatically delivers data to electronic patient journal systems. It also develops Sippcoat, a technology that hampers the formation of biofilms in urine collection and drainage systems. The company was founded in 2009 and is headquartered in Oslo, Norway.",
    "website": "http://observemedical.com",
    "zipcode": "0255"
  },
  "P99.MU": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Health Information Services",
    "long_name": "PatientSky Group AS",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PATIENTSKY GRP NK-,13736",
    "state": null,
    "summary": "PatientSky Group AS provides Software-as-a-Service (SaaS), Platform-as-a-Service (PaaS), and value added services to healthcare providers and their patients in Norway, Denmark, and Finland. It offers PatientSky 360 platform, a low-code development platform that allows vendors to interact intra-platform and reuse applications across customers, as well as platform-as-a-service partner program that provides a white labeling of the platform's modules and app. The company was founded in 2014 and is headquartered in Oslo, Norway.",
    "website": "http://www.patientsky.com",
    "zipcode": "0158"
  },
  "PCIB.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Biotechnology",
    "long_name": "PCI Biotech Holding ASA",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PCI BIOTECH HLDG",
    "state": null,
    "summary": "PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's lead product candidate is Amphinex, a photosensitiser fimaporfin. Its PCI technology is applied to three distinct anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer, which in Phase Ib clinical study in bile duct cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination; and fimaNAc, a nucleic acid therapeutics delivery technology. The company has collaborative research programs with AstraZeneca, Bavarian Nordic, BioNTech, eTheRNA immunotherapies, IMV, and Phio Pharmaceuticals. PCI Biotech Holding ASA is headquartered in Oslo, Norway.",
    "website": "http://www.pcibiotech.com",
    "zipcode": "0379"
  },
  "PHO.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Photocure ASA",
    "market": "no_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PHOTOCURE ASA",
    "state": null,
    "summary": "Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to license partners, pharmaceutical wholesalers, pharmacies, and hospitals. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway.",
    "website": "http://www.photocure.com",
    "zipcode": "0275"
  },
  "PHS.F": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Photocure ASA",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PHOTOCURE ASA  NK-,50",
    "state": null,
    "summary": "Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to license partners, pharmaceutical wholesalers, pharmacies, and hospitals. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway.",
    "website": "http://www.photocure.com",
    "zipcode": "0275"
  },
  "PSKY.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Health Information Services",
    "long_name": "PatientSky Group AS",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PATIENTSKY GROUP",
    "state": null,
    "summary": "PatientSky Group AS provides Software-as-a-Service (SaaS), Platform-as-a-Service (PaaS), and value added services to healthcare providers and their patients in Norway, Denmark, and Finland. It offers PatientSky 360 platform, a low-code development platform that allows vendors to interact intra-platform and reuse applications across customers, as well as platform-as-a-service partner program that provides a white labeling of the platform's modules and app. The company was founded in 2014 and is headquartered in Oslo, Norway.",
    "website": "http://www.patientsky.com",
    "zipcode": "0158"
  },
  "SOFTX.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Biotechnology",
    "long_name": "SoftOx Solutions AS",
    "market": "no_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SOFTOX SOLUTIONS",
    "state": null,
    "summary": "SoftOx Solutions AS, together with its subsidiaries, operates as a medtech company in Norway. Its SoftOx technology kills the microorganisms in biofilms by acting on various microbial components. The company engages in the development of SoftOx Wound Irrigation Solution that is under preclinical studies for the prevention and treatment of infections on breached or compromised skin, including acute wounds and skin lesions in patients with eczema; and SoftOx Biofilm Eradicator, which is in preclinical studies to treat biofilm infections in non-healing chronic wounds. The company was founded in 2012 and is headquartered in Oslo, Norway.",
    "website": "http://www.soft-ox.com",
    "zipcode": "0275"
  },
  "TA5.F": {
    "city": "Lysaker",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Targovax ASA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "TARGOVAX ASA  NK -,10",
    "state": null,
    "summary": "Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical studies for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen cancer vaccines targeting tumors with oncogenic RASÂmutations. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.",
    "website": "http://www.targovax.com",
    "zipcode": "1366"
  },
  "TRVX.OL": {
    "city": "Lysaker",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Biotechnology",
    "long_name": "Targovax ASA",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "TARGOVAX ASA",
    "state": null,
    "summary": "Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical studies for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen cancer vaccines targeting tumors with oncogenic RASÂmutations. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.",
    "website": "http://www.targovax.com",
    "zipcode": "1366"
  },
  "ULTI.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Biotechnology",
    "long_name": "Ultimovacs ASA",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ULTIMOVACS ASA",
    "state": null,
    "summary": "Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company engages in performing a clinical development program with clinical trials in Europe and the United States. Its lead product candidate is UV1, a peptide-based vaccine, which completed Phase I clinical trial that induces T cell response against the universal cancer antigen telomerase. The company was founded in 2011 and is headquartered in Oslo, Norway.",
    "website": "http://www.ultimovacs.com",
    "zipcode": "0379"
  },
  "VACC.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Biotechnology",
    "long_name": "Vaccibody AS",
    "market": "no_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "VACCIBODY AS",
    "state": null,
    "summary": "Vaccibody AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of melanoma, lung, head and neck, renal, and bladder; and VB10.16, a therapeutic DNA vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. The company has clinical collaboration agreements with Roche and Nektar Therapeutics. Vaccibody AS was founded in 2007 and is based in Oslo, Norway.",
    "website": "http://www.vaccibody.com",
    "zipcode": "0349"
  },
  "VISTN.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Vistin Pharma ASA",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "VISTIN PHARMA ASA",
    "state": null,
    "summary": "Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin APIs and direct compressive granulates for the pharmaceutical industry. The company was incorporated in 2015 and is headquartered in Oslo, Norway.",
    "website": "http://www.vistin.com",
    "zipcode": "0661"
  },
  "VP4.F": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Vistin Pharma ASA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "VISTIN PHARMA ASA  NK 1",
    "state": null,
    "summary": "Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin APIs and direct compressive granulates for the pharmaceutical industry. The company was incorporated in 2015 and is headquartered in Oslo, Norway.",
    "website": "http://www.vistin.com",
    "zipcode": "0661"
  }
}
